PMS2 and carcinoma: Instead of an accelerated adenoma-carcinoma pathway, our current results may indicate an accelerated stochastic pathway accounting for most CRCs in path_MSH2, path_MLH1 and path_MSH6 carriers, but not path_PMS2 carriers (Fig. 5).